• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RPTX

    Repare Therapeutics Inc.

    Subscribe to $RPTX
    $RPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small-molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, a proprietary drug discovery program for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: reparerx.com

    Peers

    $HARP
    $RUBY
    $KDNY

    Recent Analyst Ratings for Repare Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    6/9/2023$11.00 → $16.00Hold → Buy
    Stifel
    2/3/2023$28.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2023$28.00Overweight
    CapitalOne
    4/12/2022$11.00Buy → Hold
    Stifel
    3/17/2022$43.00Buy
    Goldman
    9/23/2021$48.00Buy
    Stifel
    9/13/2021$54.00Buy
    HC Wainwright & Co.
    8/16/2021$45.00 → $47.00Overweight
    Morgan Stanley
    6/28/2021$46.00Buy
    Guggenheim
    See more ratings

    Repare Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Finance and CAO Alves Sandra Isabelle Barros was granted 4,100 shares, increasing direct ownership by 16% to 29,622 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/29/25 5:07:34 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Alves Sandra Isabelle Barros claimed ownership of 25,522 shares (SEC Form 3)

      3 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/29/25 5:05:52 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP, CHIEF FINANCIAL OFFICER Forte Steve

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      4/4/25 4:15:09 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CHIEF MEDICAL OFFICER Koehler Maria sold $4,099 worth of shares (3,596 units at $1.14), decreasing direct ownership by 2% to 227,813 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      3/14/25 4:30:21 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CHIEF FINANCIAL OFFICER Forte Steve sold $7,848 worth of shares (6,884 units at $1.14), decreasing direct ownership by 11% to 54,786 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      3/14/25 4:30:15 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CHIEF SCIENTIFIC OFFICER Zinda Michael sold $6,397 worth of shares (5,611 units at $1.14), decreasing direct ownership by 7% to 80,297 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      3/14/25 4:30:19 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Segal Lloyd Mitchell sold $24,144 worth of shares (21,179 units at $1.14), decreasing direct ownership by 15% to 124,394 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      3/14/25 4:30:13 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CHIEF FINANCIAL OFFICER Forte Steve was granted 14,000 shares, increasing direct ownership by 29% to 61,670 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      3/6/25 5:00:06 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, CHIEF SCIENTIFIC OFFICER Zinda Michael was granted 14,000 shares, increasing direct ownership by 19% to 85,908 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      3/6/25 5:00:09 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Segal Lloyd Mitchell was granted 40,000 shares, increasing direct ownership by 38% to 145,573 units (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      3/6/25 5:00:12 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Repare Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

      Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

      Repare Therapeutics Inc. ("Repare") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ("DCx"), a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures. Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment. "We have taken careful steps to evaluate all aspects of our business to ensure continued value generation,

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Mini-Oral Presentation Details: Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center Session: Innovative Ap

      4/25/25 1:00:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Leadership Transitions

      Steve Forte, Executive Vice President and Chief Financial Officer, appointed as President, Chief Executive Officer and Director Lloyd M. Segal has resigned as President, Chief Executive Officer and Director to pursue other opportunities Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that Steve Forte, Executive Vice President and Chief Financial Officer, has been appointed as President and Chief Executive Officer and to the Board of Directors effective April 11, 2025. He will serve in this new role in addition to his current role as the Company's Chief Financial Officer. Lloyd M. Segal has resigned as

      3/31/25 4:39:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced that the Compensation Committee of the Company's Board of Directors granted, on November 5, 2024 and March 5, 2025, stock options to purchase an aggregate of 22,200 of the Company's common shares to two individuals pursuant to the Company's 2024 Inducement Plan. The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Repare, as an inducement material to such individual's entering into employment with Repare, in accordance with Nasdaq Listing Rule 5635(c)(4). Repare

      3/7/25 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Initial clinical readout from Phase 1 RP-3467 (Polθ ATPase/helicase inhibitor) POLAR trial expected in Q3 2025 Initial clinical readout from Phase 1 RP-1664 (PLK4 inhibitor) LIONS trial expected in Q4 2025 Company reducing its workforce by approximately 75% $152.8 million in cash and cash equivalents and marketable securities provides runway to late-2027 Exploring partnerships across portfolio, including for Lunre+Camo Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2024. "Our recently implemented re-structuring and the re-prio

      3/3/25 7:05:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

      Realigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025 Exploring partnerships for continued development of Lunre+Camo and other assets Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced a re-alignment of resources and a re-prioritization of its clinical portfolio to focus on the continued advancement of its Phase 1 clinical programs, RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor). Repare also announced its intention to seek partnering opp

      1/9/25 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

      Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 23, 2024 /PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies to improve patient outcomes. A stage 4 breast cancer patient in the United States reportedly achieved complete remission within six weeks through a novel immunotherapy approach, as highlighted by the New York Post. Meanwhile, in Europe, a Scottish woman became the first recipient of a personalized mRNA cancer vaccine, training her immune system to target cancer cells and marking a significant step toward more precise, less toxic treatments. These breakthroug

      12/23/24 10:49:00 AM ET
      $CRGX
      $IMRX
      $ONCY
      $RNXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

      Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte

      12/12/24 4:20:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

      Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D.,

      12/10/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Repare Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bvf Partners L P/Il bought $6,249,889 worth of shares (1,227,301 units at $5.09) (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      11/17/23 4:54:43 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bvf Partners L P/Il bought $2,821,352 worth of shares (783,709 units at $3.60) (SEC Form 4)

      4 - Repare Therapeutics Inc. (0001808158) (Issuer)

      11/3/23 5:37:44 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Repare Therapeutics Inc. SEC Filings

    See more
    • SEC Form 8-K filed by Repare Therapeutics Inc.

      8-K - Repare Therapeutics Inc. (0001808158) (Filer)

      5/1/25 7:08:02 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Repare Therapeutics Inc.

      DEFA14A - Repare Therapeutics Inc. (0001808158) (Filer)

      4/29/25 4:10:31 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Repare Therapeutics Inc.

      DEF 14A - Repare Therapeutics Inc. (0001808158) (Filer)

      4/29/25 4:05:33 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Repare Therapeutics Inc. (0001808158) (Filer)

      3/31/25 5:02:21 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Repare Therapeutics Inc.

      S-8 - Repare Therapeutics Inc. (0001808158) (Filer)

      3/3/25 4:06:54 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Repare Therapeutics Inc.

      10-K - Repare Therapeutics Inc. (0001808158) (Filer)

      3/3/25 7:55:46 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Repare Therapeutics Inc. (0001808158) (Filer)

      3/3/25 7:13:51 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Repare Therapeutics Inc.

      SCHEDULE 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      2/14/25 11:23:34 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Repare Therapeutics Inc.

      SCHEDULE 13D/A - Repare Therapeutics Inc. (0001808158) (Subject)

      1/31/25 4:15:30 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Repare Therapeutics Inc.

      SCHEDULE 13D/A - Repare Therapeutics Inc. (0001808158) (Subject)

      1/15/25 6:43:01 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Repare Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    Repare Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 9:00:57 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 5:05:19 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Repare Therapeutics Inc.

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/14/24 9:42:55 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Repare Therapeutics Inc.

      SC 13G - Repare Therapeutics Inc. (0001808158) (Subject)

      2/14/24 9:02:34 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Repare Therapeutics Inc. (Amendment)

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      2/14/24 4:26:22 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Repare Therapeutics Inc. (Amendment)

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      2/14/24 8:54:27 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Repare Therapeutics Inc. (Amendment)

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      1/29/24 4:01:01 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Repare Therapeutics Inc. (Amendment)

      SC 13D/A - Repare Therapeutics Inc. (0001808158) (Subject)

      11/17/23 4:52:59 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Repare Therapeutics Inc.

      SC 13D - Repare Therapeutics Inc. (0001808158) (Subject)

      11/3/23 5:20:05 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Repare Therapeutics Inc. (Amendment)

      SC 13G/A - Repare Therapeutics Inc. (0001808158) (Subject)

      2/14/23 4:29:07 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics upgraded by Stifel with a new price target

      Stifel upgraded Repare Therapeutics from Hold to Buy and set a new price target of $16.00 from $11.00 previously

      6/9/23 7:34:45 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Repare Therapeutics from Overweight to Equal-Weight and set a new price target of $15.00 from $28.00 previously

      2/3/23 7:35:18 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Repare Therapeutics with a new price target

      CapitalOne initiated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $28.00

      1/6/23 8:30:21 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Repare Therapeutics from Buy to Hold and set a new price target of $11.00

      4/12/22 7:35:26 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman resumed coverage on Repare Therapeutics with a new price target

      Goldman resumed coverage of Repare Therapeutics with a rating of Buy and set a new price target of $43.00

      3/17/22 7:09:04 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Repare Therapeutics with a new price target

      Stifel initiated coverage of Repare Therapeutics with a rating of Buy and set a new price target of $48.00

      9/23/21 5:00:53 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Repare Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Repare Therapeutics with a rating of Buy and set a new price target of $54.00

      9/13/21 6:36:05 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley reiterated coverage on Repare Therapeutics with a new price target

      Morgan Stanley reiterated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $47.00 from $45.00 previously

      8/16/21 9:07:15 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Repare Therapeutics with a new price target

      Guggenheim initiated coverage of Repare Therapeutics with a rating of Buy and set a new price target of $46.00

      6/28/21 5:36:35 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley reiterated coverage on Repare Therapeutics with a new price target

      Morgan Stanley reiterated coverage of Repare Therapeutics with a rating of Overweight and set a new price target of $45.00 from $41.00 previously

      4/19/21 11:06:53 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Repare Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

      Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut

      5/1/25 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

      Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks, comparing favorably to current standard of care Company plans to initiate a registrational Phase 3 trial of lunresertib in combination with camonsertib in endometrial cancer in 2H 2025 Repare to host conference call and webcast today at 4:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reporte

      12/12/24 4:20:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

      Event to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib in combination with camonsertib at the recommended Phase 2 dose in an expansion cohort in patients with platinum-resistant ovarian and endometrial cancers harboring CCNE1 amplification or FBXW7 or PPP2R1A mutations, on Thursday, December 12, 2024 at 4:30 p.m. Eastern Time. Repare's executive management team will be joined by Brian Slomovitz, M.D.,

      12/10/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Week in Canadian Press Releases: 10 Stories You Need to See

      A roundup of the most newsworthy press releases from Cision Distribution this week TORONTO, May 31, 2024 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that

      5/31/24 6:18:00 AM ET
      $CM
      $RPTX
      $RY
      Commercial Banks
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor

      RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies RP-3467 demonstrated complete, sustained regressions preclinically in combination with PARPi, and compelling anti-tumor activity in combination with radioligand therapy (RLT) and chemotherapy Company expects to initiate clinical trials of RP-1664 in 1H 2024 and RP-3467 in 2H 2024 Repare to host conference call and webcast today at 8:00 a.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development progra

      11/15/23 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

      Presented positive initial data from ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors Repare to host conference call and webcast to discuss latest data from its preclinical programs and overall pipeline, November 15th, 2023 at 8:00 a.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023. "We substantially advanced our pipeline during the third quarter, particularly our Phase

      11/9/23 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast

      Event to be webcast live on Wednesday, November 15 at 8:00 a.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, a newly designated Polθ inhibitor, on Wednesday, November 15, 2023 at 8:00 a.m. Eastern Time. Conference Call and Webcast Details: To access the call, please dial (877) 870-4263 (U.S. and Canada) or (412) 317-0790 (international) at least 10 minutes prior to the start time and ask to be joined to the Repare Therapeutics call. A live webcast will be ava

      11/7/23 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

      Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all selected genotypes Overall response of 33.3% across all tumor types and 50% RECIST response in patients with heavily pre-treated gynecologic tumors, including endometrial, ovarian and cervical, at the preliminary recommended phase 2 dose Encouraging safety and tolerability profile observed as monotherapy and in combination with camonsertib Repare to host conference call and webcast today at 5:30 p.m. ET to discuss these results Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reported

      10/13/23 9:40:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

      Conference call and live webcast on Friday, October 13, 2023 at 5:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to share initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial that will be presented in a plenary session at the upcoming AACR-NCI-EORTC conference, being held October 11-15, 2023 in Boston, MA. The data that will be presented at AACR-NCI-EORTC will be based on a later cutoff date than what is included in the abstracts, which are released on Wednesday, October 4, 2023 at 12:00 p.m. ET. Repare's executive ma

      10/3/23 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights

      Event to be webcast live on Wednesday, June 7, 2023 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time. RP-6306 is a first-in-class, oral PKMYT1 (Protein Kinase Membrane-associated tyrosine- and threonine- specific cdc-2 inhibitory kinase) synthetic lethal inhibitor in clinical development for the treatment of molecularly selecte

      6/2/23 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Repare Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

      Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D             First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating Phase 2 TRESR expansion in ~20 patients evaluating monotherapy camonsertib in NSCLC; initial data expected in 2025 First patient dosed in Phase 1 LIONS monotherapy trial for PLK4 inhibitor RP-1664 Announced the appointment of Steven H. Stein, M.D. to Repare's Board of Directors, effecti

      5/7/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term as a Class I director on June 17, 2024, after serving more than seven years on the Board. "On behalf of the Company and our Board of Directors, we thank Todd for his dedication and partnership, which have played a crucial role in shaping Repare

      4/26/24 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. "We significantly advanced our pipeline in 2023 and presented strong data from key programs, notably for lunresertib in combination with camonsertib, and for camonsertib in combination with PARP inhibitors. In addition, we presented compelling preclinical data sets for RP-3467, which we're developing as a potential best-in-class Polθ inhibitor, and for RP-1664, a potential first- and best-in-class PLK4 inhibitor," said Lloyd M. Segal, President and Chief Executive Officer of Repare. "2

      1/8/24 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Repare Therapeutics Inc., (NASDAQ:RPTX), ("Repare", or "the Company"), a leading clinical-stage precision oncology company, today announced that, in connection with the appointment of Daniel Belanger as the Company's EVP, Human Resources, the Company granted Mr. Belanger an inducement stock option to purchase an aggregate of 240,000 of the Company's common shares. The award was approved by the Compensation Committee of the Company's Board of Directors and was granted outside of the Company's 2020 Equity Incentive Plan, with a grant date of May 18, 2023, as an inducement material to Mr. Belanger entering into employment with Repare, in accordance with Nasdaq Listing Rule 5635(c)(4). The st

      5/22/23 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

      Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting Camonsertib combination therapy showed 48% CBR across tumor types regardless of choice of PARP inhibitor or platinum resistance, with a favorable safety and tolerability profile Company on track to report initial RP-6306 monotherapy data from Phase 1 MYTHIC clinical trial in June 2023 Announced the appointment of Susan Molineaux, Ph.D., and departure of Jerel Davis, Ph.D. on our Board of Directors, as well as the addition of Daniel Belanger to the senior leadership team Repare Therapeutics Inc. ("Repare" or the "Company") (NA

      5/9/23 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors

      Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the Company's upcoming annual meeting of shareholders in June 2023. Concurrent with Dr. Molineaux's appointment as of the date of the annual meeting, Jerel Davis, Ph.D., Managing Director at Versant Ventures and a founding member of Repare's Board of Directors, will step down from the Board. "On behalf of the Company and our Board of Directors, I want to thank Jerel for his service and partnership that have been instrumental in building Repare into the leadi

      4/28/23 4:05:00 PM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development

      Former CCO of Y-mAbs Therapeutics brings 20 years of pharma and biotech commercial leadership  Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Philip Herman as its EVP Commercial & New Product Development. "We are excited to welcome Phil to Repare as we are looking forward to key catalysts for RP-3500 and RP-6306 in 2022. 2022 will be an important year for us as we continue to build Repare into the leading precision oncology company delivering synthetic lethality medicines that meaningfully improve the lives of cancer patients," said Lloyd M. Segal, President and Chief Executive Of

      1/5/22 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman

      Former CEO of Five Prime Therapeutics brings over 25 years of leadership and commercial experience in pharma, biotech and molecular Dx Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Thomas Civik to its Board of Directors and as its Chairman. He replaces Jerel Davis, Ph.D., Managing Director at Versant Ventures, who will remain a member of the Company's Board. "It is my pleasure to welcome Tom to our Board as our new Chairman," said Repare President and CEO Lloyd M. Segal. "Tom brings a wealth of experience in developing and launching innovative oncology drugs and in leading edge mo

      9/7/21 7:00:00 AM ET
      $RPTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors

      Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena"), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the appointment of Maria Koehler, M.D., Ph.D. to its Board of Directors. Dr. Koehler is a board-certified hematologist and oncologist with more than 20 years of pharmaceutical and biotech oncology experience in clinical development, including senior roles at Pfizer where she led the development of Ibrance® (palbociclib) and contributed to the strategic direction of the oncology portfolio. "We are extremely pleased to welcome Maria to our Board of Directors at this important next stage

      4/15/21 7:00:00 AM ET
      $RPTX
      $BCYC
      $IKNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)